conserv bioscience limited
conserv bioscience limited Company Information
Company Number
12930143
Website
http://seekacure.comRegistered Address
the walbrook building, 25 walbrook, london, EC4N 8AF
Industry
Manufacture of pharmaceutical preparations
Telephone
02076913577
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
peptcell limited 100%
conserv bioscience limited Estimated Valuation
Pomanda estimates the enterprise value of CONSERV BIOSCIENCE LIMITED at £553.4k based on a Turnover of £436.8k and 1.27x industry multiple (adjusted for size and gross margin).
conserv bioscience limited Estimated Valuation
Pomanda estimates the enterprise value of CONSERV BIOSCIENCE LIMITED at £4.5k based on an EBITDA of £795 and a 5.69x industry multiple (adjusted for size and gross margin).
conserv bioscience limited Estimated Valuation
Pomanda estimates the enterprise value of CONSERV BIOSCIENCE LIMITED at £0 based on Net Assets of £-131.3k and 2.46x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Conserv Bioscience Limited Overview
Conserv Bioscience Limited is a live company located in london, EC4N 8AF with a Companies House number of 12930143. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in October 2020, it's largest shareholder is peptcell limited with a 100% stake. Conserv Bioscience Limited is a startup, micro sized company, Pomanda has estimated its turnover at £436.8k with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Conserv Bioscience Limited Health Check
Pomanda's financial health check has awarded Conserv Bioscience Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
2 Strong
2 Regular
5 Weak
Size
annual sales of £436.8k, make it smaller than the average company (£25.5m)
- Conserv Bioscience Limited
£25.5m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Conserv Bioscience Limited
- - Industry AVG
Production
with a gross margin of 31.7%, this company has a comparable cost of product (31.7%)
- Conserv Bioscience Limited
31.7% - Industry AVG
Profitability
an operating margin of -4.2% make it less profitable than the average company (6%)
- Conserv Bioscience Limited
6% - Industry AVG
Employees
with 2 employees, this is below the industry average (93)
2 - Conserv Bioscience Limited
93 - Industry AVG
Pay Structure
on an average salary of £57.2k, the company has an equivalent pay structure (£57.2k)
- Conserv Bioscience Limited
£57.2k - Industry AVG
Efficiency
resulting in sales per employee of £218.4k, this is less efficient (£282.5k)
- Conserv Bioscience Limited
£282.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Conserv Bioscience Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 50 days, this is slower than average (36 days)
- Conserv Bioscience Limited
36 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Conserv Bioscience Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 21 weeks, this is more cash available to meet short term requirements (7 weeks)
21 weeks - Conserv Bioscience Limited
7 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 145.3%, this is a higher level of debt than the average (44.4%)
145.3% - Conserv Bioscience Limited
44.4% - Industry AVG
CONSERV BIOSCIENCE LIMITED financials
Conserv Bioscience Limited's latest turnover from December 2023 is estimated at £436.8 thousand and the company has net assets of -£131.3 thousand. According to their latest financial statements, Conserv Bioscience Limited has 2 employees and maintains cash reserves of £30.4 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|
| Turnover | |||
| Other Income Or Grants | |||
| Cost Of Sales | |||
| Gross Profit | |||
| Admin Expenses | |||
| Operating Profit | |||
| Interest Payable | |||
| Interest Receivable | |||
| Pre-Tax Profit | |||
| Tax | |||
| Profit After Tax | |||
| Dividends Paid | |||
| Retained Profit | |||
| Employee Costs | |||
| Number Of Employees | 2 | ||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|
| Tangible Assets | 75,534 | 0 | 0 |
| Intangible Assets | 11,845 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 |
| Total Fixed Assets | 87,379 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 |
| Misc Debtors | 172,149 | 45,587 | 14 |
| Cash | 30,374 | 93,569 | 424 |
| misc current assets | 0 | 0 | 0 |
| total current assets | 202,523 | 139,156 | 438 |
| total assets | 289,902 | 139,156 | 438 |
| Bank overdraft | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 |
| Trade Creditors | 41,227 | 23,790 | 0 |
| Group/Directors Accounts | 0 | 0 | 1,082 |
| other short term finances | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 |
| other current liabilities | 33,409 | 0 | 0 |
| total current liabilities | 74,636 | 23,790 | 1,082 |
| loans | 346,532 | 201,083 | 0 |
| hp & lease commitments | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 |
| total long term liabilities | 346,532 | 201,083 | 0 |
| total liabilities | 421,168 | 224,873 | 1,082 |
| net assets | -131,266 | -85,717 | -644 |
| total shareholders funds | -131,266 | -85,717 | -644 |
| Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|
| Operating Activities | |||
| Operating Profit | |||
| Depreciation | 19,324 | 0 | 0 |
| Amortisation | 0 | 0 | 0 |
| Tax | |||
| Stock | 0 | 0 | 0 |
| Debtors | 126,562 | 45,573 | 14 |
| Creditors | 17,437 | 23,790 | 0 |
| Accruals and Deferred Income | 33,409 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 |
| Cash flow from operations | |||
| Investing Activities | |||
| capital expenditure | |||
| Change in Investments | 0 | 0 | 0 |
| cash flow from investments | |||
| Financing Activities | |||
| Bank loans | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | -1,082 | 1,082 |
| Other Short Term Loans | 0 | 0 | 0 |
| Long term loans | 145,449 | 201,083 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 |
| share issue | |||
| interest | |||
| cash flow from financing | |||
| cash and cash equivalents | |||
| cash | -63,195 | 93,145 | 424 |
| overdraft | 0 | 0 | 0 |
| change in cash | -63,195 | 93,145 | 424 |
conserv bioscience limited Credit Report and Business Information
Conserv Bioscience Limited Competitor Analysis
Perform a competitor analysis for conserv bioscience limited by selecting its closest rivals, whether from the MANUFACTURING sector, other micro companies, companies in EC4N area or any other competitors across 12 key performance metrics.
conserv bioscience limited Ownership
CONSERV BIOSCIENCE LIMITED group structure
Conserv Bioscience Limited has no subsidiary companies.
conserv bioscience limited directors
Conserv Bioscience Limited currently has 3 directors. The longest serving directors include Mr Richard Huston (Oct 2020) and Kimbell Duncan (Oct 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Richard Huston | England | 63 years | Oct 2020 | - | Director |
| Kimbell Duncan | United Kingdom | 59 years | Oct 2020 | - | Director |
| Mr Kimbell Duncan | United Kingdom | 59 years | Oct 2020 | - | Director |
P&L
December 2023turnover
436.8k
+178%
operating profit
-18.5k
0%
gross margin
31.7%
-8.17%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-131.3k
+0.53%
total assets
289.9k
+1.08%
cash
30.4k
-0.68%
net assets
Total assets minus all liabilities
Similar Companies
conserv bioscience limited company details
company number
12930143
Type
Private limited with Share Capital
industry
21200 - Manufacture of pharmaceutical preparations
incorporation date
October 2020
age
4
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
TC GROUP
auditor
-
address
the walbrook building, 25 walbrook, london, EC4N 8AF
Bank
-
Legal Advisor
-
conserv bioscience limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to conserv bioscience limited.
conserv bioscience limited Companies House Filings - See Documents
| date | description | view/download |
|---|
